Weekly Policy Blog: PDAB Deems One of Two Drugs “Unaffordable” in Recent Affordability Decisions 

On Friday, February 16, the Colorado Prescription Drug Affordability Board (PDAB or Board) completed its second and third affordability reviews, following its first decision on December 8 that the cystic fibrosis drug Trikafta is “not unaffordable.” The PDAB unanimously voted that the autoimmune disease drug Enbrel is “unaffordable for Colorado consumers” but that the HIV drug Genvoya is “not unaffordable for Colorado consumers.” The Board will decide on February 23 whether to begin the rulemaking process to establish an “upper payment limit” (UPL) for Enbrel, which would mark the first time a state has moved to cap the price of a prescription drug with a UPL. 

The PDAB’s February 16 Meeting

Enbrel Affordability Review: PDAB staff first reviewed the draft Affordability Review Report for Enbrel and allowed Board members to ask questions and provide thoughts and feedback. In addition to PDAB…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks